AI Verdict
MSFT has stronger fundamentals based on our AI analysis.
KURA vs MSFT Fundamental Comparison
| Metric | KURA | MSFT |
|---|---|---|
| Revenue | $67.5M | $158.9B |
| Net Income | $-278.7M | $66.2B |
| Net Margin | -412.9% | 41.7% |
| ROE | -160.0% | 16.9% |
| ROA | -37.7% | 10.0% |
| Current Ratio | 6.06x | 1.39x |
| Debt/Equity | 0.06x | 0.10x |
| EPS | $-3.18 | $8.87 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KURA vs MSFT: Frequently Asked Questions
Is KURA or MSFT a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MSFT has stronger fundamentals. KURA is rated HOLD (72% confidence) while MSFT is rated BUY (91% confidence). This is not investment advice.
How does KURA compare to MSFT fundamentally?
Kura Oncology, Inc. has ROE of -160.0% vs MICROSOFT CORP's 16.9%. Net margins are -412.9% vs 41.7% respectively.
Which stock pays higher dividends, KURA or MSFT?
KURA has a dividend yield of N/A or no dividend while MSFT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KURA or MSFT for long term?
For long-term investing, consider that KURA has HOLD rating with 72% confidence, while MSFT has BUY rating with 91% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KURA vs MSFT?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KURA vs MSFT, the AI consensus favors MSFT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.